Skip to main content

Cerus Corporation to Participate in Upcoming Investor Conferences

Cerus Corporation (Nasdaq: CERS) announced today that the Company will participate in two upcoming investor conferences.

  • William ‘Obi’ Greenman, Cerus’ president and chief executive officer, is scheduled to be in attendance at BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 14th and Wednesday, February 15th.
  • William ‘Obi’ Greenman and Kevin Green, Cerus’ vice president and chief financial officer, are scheduled to participate in a fireside chat at Cowen’s 43rd Annual Health Care Conference on Wednesday, March 8th at 1:30 PM EST. A live webcast of the fireside chat will be available at A replay will be available after the event.


Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.


Joel Trujillo – Senior Director, Investor Relations

Cerus Corporation


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.